Topics:

Rheumatoid Arthritis

Five Reasons Your Patients Should Join Arthritis Power

A new symptom-tracking app isn't merely about helping your patients. It's about helping them help everyone with their condition by sharing their experience in a systematic way. Founder Jeffrey Curtis MD describes the new registry and its goals.

Rheumatoid Arthritis

rheumatoid arthritis

One very targeted clue to treatment failure: An observational study from Israel identifies Sephardic Jews as more likely than Ashkenazim to form antibodies against the biologic drug infliximab.

rheumatoid arthritis

In the second installment of a slide show based on an animated discussion by members of the rheumatology journal club (#rheumjc), partipants focus on the benefits, risks, and realities of tapering biologics in clinical practice.

rheumatoid arthritis

Slides present key points from a Twitter-based journal club, pondering a randomized study of tapering TNF inhibitors in rheumatoid arthritis. Many questions about the study design. More ask about practices already in use (addressed in Part 2).

A meta-analysis involving more than 40,000 patients finds that biologics have a 30% increased infection risk compared to DMARDs, which is greatest for patients who have also used methotrexate.

A new app-based registry focusing on rheumatoid and psoriatic arthritis and ankylosing spondylitis aims to use patient-generated data to resolve important unanswered clinical questions. Its rheumatologist sponsor urges you to encourage patients to join up.

Studies on banked cells from humans in different regions of the world reveal that many genes that control immune function behave differently in winter and summer. They are more pro-inflammatory in the winter.

Top reports chosen by Annals of Internal Medicine include several on biologics for rheumatoid arthritis and psoriatic arthritis, and mechanisms for lupus and scleroderma.

Pages

Subscribe to Rheumatoid Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.